Capital International Inc. CA Acquires 97,550 Shares of Boston Scientific Co. (NYSE:BSX)

Capital International Inc. CA raised its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 193.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 148,059 shares of the medical equipment provider’s stock after purchasing an additional 97,550 shares during the period. Capital International Inc. CA’s holdings in Boston Scientific were worth $13,225,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in BSX. Vanguard Group Inc. increased its position in Boston Scientific by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider’s stock valued at $11,869,805,000 after buying an additional 1,600,062 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock valued at $3,230,293,000 after acquiring an additional 3,344,571 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Boston Scientific by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider’s stock worth $2,729,371,000 after purchasing an additional 1,041,329 shares during the last quarter. Capital World Investors boosted its stake in Boston Scientific by 28.7% in the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock worth $2,492,041,000 after purchasing an additional 6,216,199 shares in the last quarter. Finally, Norges Bank purchased a new stake in Boston Scientific during the 4th quarter valued at about $1,762,522,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.2 %

Shares of BSX stock opened at $95.08 on Friday. The stock has a fifty day simple moving average of $99.46 and a two-hundred day simple moving average of $94.41. Boston Scientific Co. has a 52-week low of $66.80 and a 52-week high of $107.17. The firm has a market capitalization of $140.63 billion, a PE ratio of 76.06, a PEG ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, CFO Daniel J. Brennan sold 15,087 shares of the firm’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the completion of the transaction, the chief financial officer now directly owns 241,451 shares of the company’s stock, valued at approximately $25,369,256.57. This trade represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares of the company’s stock, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 133,183 shares of company stock valued at $13,948,476. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BSX. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 8th. Barclays upped their price objective on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. UBS Group upped their price target on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Stifel Nicolaus upped their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $113.00 price objective for the company in a report on Wednesday. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $110.22.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.